PMDA notice: Nitrosamine detection in Rizatriptan OD Tablets 10 mg "TCK"
「リザトリプタンOD錠 10mg「TCK」 ニトロソアミン化合物検出のお知らせ」を掲載しました
Published: 2026-10-28 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-10-29
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
这是该更新的中文摘要，并非完整法改解读；请同时核实日文官方原文。
摘要
2026-10-28，医药品医疗器械综合机构（PMDA）宣布，已发布关于利扎曲普坦口腔崩解片10 mg「TCK」检出亚硝胺化合物的通知。所提供的标题未说明检出水平、受影响批次，也未说明任何召回或其他应对措施。
对企业的影响
使用利扎曲普坦口腔崩解片10 mg「TCK」的医疗专业人员和患者可能受到这项特定产品安全通知的影响，但仅凭标题无法确定其实际影响。
建议采取的措施
查阅PMDA官方通知将有助于明确受影响的产品范围、检出详情以及通知中载明的任何应对措施。
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2026-10-28, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted a notice concerning detection of a nitrosamine compound in Rizatriptan OD Tablets 10 mg "TCK". The supplied title does not specify the detected level, affected batches, or any recall or other response.
Business Impact
Healthcare professionals and patients using Rizatriptan OD Tablets 10 mg "TCK" may be affected by the product-specific safety notice, but its practical implications cannot be determined from the title alone.
Recommended Action
Review of the official PMDA notice would help establish the affected product scope, detection details, and any stated response measures.